Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 7

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 7
---
pandemic. As the approved indication is for travel medicine, and international travel was substantially impacted by the pandemic, we did
not undertake any active marketing efforts for Arakoda. Following our financing in January 2024, the Company hired a Chief Commercial
Officer and commissioned IQVIA market data and a qualitative marketing demand study. That research, recently completed, suggests that
prescribing for malaria prevention therapies has returned to pre-pandemic levels, and that the total U.S. market represents around 1.1
million prescriptions (one prescription per three weeks of travel). Based on consumer and HCP demand research, the Company estimates that
the accessible market for Arakoda represents about one third of this volume (about 330,000 prescriptions). Barriers to entry include low
brand awareness in the prescriber community and the low cost of some of the generic alternatives. We are conducting a pilot commercialization
study to confirm these barriers can be overcome (see “Strategy”).

<div align='center'>S-1</div>

Treatment and Prevention of Tick-Borne Disease (Babesiosis) We are repositioning the Arakoda regimen of Tafenoquine for several potential new therapeutic indications that have substantial U.S. caseloads, as further described below:

| ● | Treatment                                                                                                                                      
 of Chronic Tick-Borne Disease (Babesiosis). Babesia parasites are co-transmitted by the same ticks that transmit Borrelia,                     
 the Lyme disease bacterium. Although Lyme in the acute phase is generally viewed by the medical community as being treatable with antibiotics, 
 individuals who are not treated, or fail treatment, may go on to develop long term, and potentially debilitating, chronic symptoms such        
 as fatigue, body aches, and cognitive problems.1 This condition is defined by the Centers for Disease Control and Prevention                   
 (“CDC”) as Post-Treatment Lyme Disease Syndrome (“PTLDS”) or simply as Lyme in the patient community.1 Although                                
 there are no published estimates, key opinion leaders have stated that as many as 50% of Lyme/PTLDS patients are believed to be co-infected    
 with Babesia parasites, a diagnosis referred to in the Lyme community as “Chronic Babesiosis.” Prescribers                                     
 in the Lyme disease community utilize a number of therapeutic modalities to manage the symptoms of Chronic Babesiosis, including FDA-approved  
 pharmaceuticals such as atovaquone and azithromycin (these are assumed to suppress the